TNX 2600
Alternative Names: TNX-2600Latest Information Update: 21 Sep 2020
At a glance
- Originator University of Kansas
- Developer Tonix Pharmaceuticals Holding Corp; University of Kansas
- Class COVID-19 vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections